A phase I/IIa trial of of a novel therapeutic anti-cancer DNA vaccine, Elenagen in terminally ill cancer patients

Trial Profile

A phase I/IIa trial of of a novel therapeutic anti-cancer DNA vaccine, Elenagen in terminally ill cancer patients

Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Apr 2017

At a glance

  • Drugs P62-cancer-dna-vaccine CureLab Oncology (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Apr 2017 New trial record
    • 28 Mar 2017 According to a CureLab Oncology media release, results from this trial have been published in Oncotarget.
    • 28 Mar 2017 Results published in a CureLab Oncology media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top